@prefix : <http://www.transceleratebiopharmainc.com/LY246708/V1#> .
@prefix pr: <http://www.assero.co.uk/Protocol#> .
@prefix isoC: <http://www.assero.co.uk/ISO11179Concepts#> .
@prefix isoT: <http://www.assero.co.uk/ISO11179Types#> .
@prefix isoR: <http://www.assero.co.uk/ISO11179Registration#> .
@prefix isoI: <http://www.assero.co.uk/ISO11179Identification#> .
@prefix bo: <http://www.assero.co.uk/BusinessOperational#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .

<http://www.transceleratebiopharmainc.com/LY246708/V1>
	rdf:type owl:Ontology ;
.
<http://www.assero.co.uk/EP#099d795a-2b39-4fb9-beb0-19a630c82d71>
	rdf:type pr:Epoch ;
	isoC:label "Screening"^^xsd:string ;
	pr:ordinal "1"^^xsd:integer ;
.
<http://www.assero.co.uk/EP#b343ffac-2569-4bb5-96a7-0775a02b19eb>
	rdf:type pr:Epoch ;
	isoC:label "Treatment"^^xsd:string ;
	pr:ordinal "2"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#4f75fc61-3550-482b-a143-761f59075859>
	rdf:type pr:Arm ;
	isoC:label "High Dose"^^xsd:string ;
	pr:description "High Dose"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "1"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#4e574b6e-bc94-406c-ba98-538336979c99>
	rdf:type pr:Arm ;
	isoC:label "Low Dose"^^xsd:string ;
	pr:description "Low Dose"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "2"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#b69e18aa-fcde-4e28-9379-ad64b06d4d14>
	rdf:type pr:Arm ;
	isoC:label "Placebo"^^xsd:string ;
	pr:description "Placebo"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "3"^^xsd:integer ;
.
<http://www.assero.co.uk/ELE#499b4487-f0ef-4755-bdf5-a9eb93d3f742>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#4f75fc61-3550-482b-a143-761f59075859> ;
	pr:inEpoch <http://www.assero.co.uk/EP#099d795a-2b39-4fb9-beb0-19a630c82d71> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#b907b5c6-8b01-43ca-9201-b0a1921c7a00> ;
.
<http://www.assero.co.uk/ELE#2a4787a0-c43c-48fc-9afd-2231e26ff27b>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#4e574b6e-bc94-406c-ba98-538336979c99> ;
	pr:inEpoch <http://www.assero.co.uk/EP#099d795a-2b39-4fb9-beb0-19a630c82d71> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#b907b5c6-8b01-43ca-9201-b0a1921c7a00> ;
.
<http://www.assero.co.uk/ELE#e6b3bd4b-9e82-40cb-b0af-0f9bed40c269>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#b69e18aa-fcde-4e28-9379-ad64b06d4d14> ;
	pr:inEpoch <http://www.assero.co.uk/EP#099d795a-2b39-4fb9-beb0-19a630c82d71> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#b907b5c6-8b01-43ca-9201-b0a1921c7a00> ;
.
<http://www.assero.co.uk/ELE#131a1a38-2638-44e5-97f6-68f4b218acb4>
	rdf:type pr:Element ;
	isoC:label "High Dose"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#4f75fc61-3550-482b-a143-761f59075859> ;
	pr:inEpoch <http://www.assero.co.uk/EP#b343ffac-2569-4bb5-96a7-0775a02b19eb> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#cef7146f-5b0d-4ce1-b4f6-f5d2f9036e67> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#08856e86-7c54-47f9-9499-d93a3ca00f03> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#902b4d94-9e29-498e-a3a7-e7a1925d1b92> ;
.
<http://www.assero.co.uk/ELE#18490e5d-8a70-4a83-8f2c-8bd745ce8b41>
	rdf:type pr:Element ;
	isoC:label "Low Dose"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#4e574b6e-bc94-406c-ba98-538336979c99> ;
	pr:inEpoch <http://www.assero.co.uk/EP#b343ffac-2569-4bb5-96a7-0775a02b19eb> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#cef7146f-5b0d-4ce1-b4f6-f5d2f9036e67> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#08856e86-7c54-47f9-9499-d93a3ca00f03> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#902b4d94-9e29-498e-a3a7-e7a1925d1b92> ;
.
<http://www.assero.co.uk/ELE#9ecfc307-7821-43f8-949c-aaf0d44593a9>
	rdf:type pr:Element ;
	isoC:label "Placebo"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#b69e18aa-fcde-4e28-9379-ad64b06d4d14> ;
	pr:inEpoch <http://www.assero.co.uk/EP#b343ffac-2569-4bb5-96a7-0775a02b19eb> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#cef7146f-5b0d-4ce1-b4f6-f5d2f9036e67> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#08856e86-7c54-47f9-9499-d93a3ca00f03> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#902b4d94-9e29-498e-a3a7-e7a1925d1b92> ;
.
:PR
	rdf:type pr:Protocol ;
	isoC:label "LY246708"^^xsd:string ;
	isoT:hasState :PR_RS ;
	isoT:hasIdentifier :PR_SI ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T08:18:55+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "H2Q-MC-LZZT"^^xsd:string ;
	pr:title "Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimerâ€™s Disease."^^xsd:string ;
	pr:shortTitle ""^^xsd:string ;
	pr:studyPhase :PR_TUC3 ;
	pr:studyType :PR_TUC4 ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_ALZ/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_NSD/V1#TA> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#4f75fc61-3550-482b-a143-761f59075859> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#4e574b6e-bc94-406c-ba98-538336979c99> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#b69e18aa-fcde-4e28-9379-ad64b06d4d14> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#099d795a-2b39-4fb9-beb0-19a630c82d71> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#b343ffac-2569-4bb5-96a7-0775a02b19eb> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#c95f179a-4145-4baa-8f9b-38acb92c231a> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#8e2a7283-b37b-4fc7-8e40-010237c76845> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#099a3fb9-8c0c-4c1d-a02e-6503fa74503c> ;
	pr:specifiesObjective <http://www.assero.co.uk/IC#cda5dd26-c854-40e3-a7d8-df8b4ac3085b> ;
.
:PR_RS
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
:PR_SI
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "LY246708"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
:PR_TUC3
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15601> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
:PR_TUC4
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC1>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "1"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99076/V55#C99076_C82639> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC2>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "2"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66735/V4#C66735_C15228> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "DS8500-A-U202"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T08:18:55+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle ""^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_DIA/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_M/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "DS8500-A-U202"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15600> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/DS8500-A-U202/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "CPT_TALib-RA-BWE_V002"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T08:18:55+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle ""^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_RA/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_I/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "CPT_TALib-RA-BWE_V002"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15600> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-RA-BWE_V002/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C16084> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "FLU 001"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T08:18:55+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle ""^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_INF/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_V/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "FLU001"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15602> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "CPT_TALib-Alzheimers-BWE_V003"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-19T08:18:55+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle ""^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_ALZ/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_NSD/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "CPT_TALib-ALZ-BWE_V003"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C49686> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALib-ALZ-BWE_V003/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98722> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.assero.co.uk/VI#cde782be8b675144b1c3a413d952e5058ca53d38>
	rdf:type pr:Visit ;
	isoC:label "Baseline"^^xsd:string ;
	pr:shortName "BL"^^xsd:string ;
.
<http://www.assero.co.uk/VI#e96a2145277171a0c3f5deddef4f400c2e693123>
	rdf:type pr:Visit ;
	isoC:label "Week 8"^^xsd:string ;
	pr:shortName "Wk8"^^xsd:string ;
.
<http://www.assero.co.uk/VI#4d7196ccd76ee7d4b198c45b837180508d93f61e>
	rdf:type pr:Visit ;
	isoC:label "Week 12"^^xsd:string ;
	pr:shortName "Wk12"^^xsd:string ;
.
<http://www.assero.co.uk/VI#22b0f0c8d6218cbc9e10ab1b91c9e1f800cb4f83>
	rdf:type pr:Visit ;
	isoC:label "Week 16"^^xsd:string ;
	pr:shortName "Wk16"^^xsd:string ;
.
<http://www.assero.co.uk/VI#409a2e79a0b954569269055689ebe4053add5292>
	rdf:type pr:Visit ;
	isoC:label "Week 24"^^xsd:string ;
	pr:shortName "Wk24"^^xsd:string ;
.
<http://www.assero.co.uk/TP#b907b5c6-8b01-43ca-9201-b0a1921c7a00>
	rdf:type pr:Timepoint ;
	isoC:label "TP1"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#1c9dea95-7da9-4d32-a8df-da1126424afe> ;
	pr:inVisit <http://www.assero.co.uk/VI#cde782be8b675144b1c3a413d952e5058ca53d38> ;
	pr:hasPlanned <http://www.assero.co.uk/IC#4fea5c2e-2842-47bc-937f-79cafbf73164> ;
.
<http://www.assero.co.uk/TP#cef7146f-5b0d-4ce1-b4f6-f5d2f9036e67>
	rdf:type pr:Timepoint ;
	isoC:label "TP2"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#88eabc08-fa7f-4058-a6ad-71bf8a9ccf39> ;
	pr:inVisit <http://www.assero.co.uk/VI#e96a2145277171a0c3f5deddef4f400c2e693123> ;
	pr:hasPlanned <http://www.assero.co.uk/IC#344ffd58-3193-40f7-9992-0908a80e17f6> ;
.
<http://www.assero.co.uk/TP#08856e86-7c54-47f9-9499-d93a3ca00f03>
	rdf:type pr:Timepoint ;
	isoC:label "TP3"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#6800ec9c-467d-4f09-a580-48ab7899ff45> ;
	pr:inVisit <http://www.assero.co.uk/VI#4d7196ccd76ee7d4b198c45b837180508d93f61e> ;
.
<http://www.assero.co.uk/TP#902b4d94-9e29-498e-a3a7-e7a1925d1b92>
	rdf:type pr:Timepoint ;
	isoC:label "TP4"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#8be0c03d-1fb0-48e6-831e-40dd78b8beaa> ;
	pr:inVisit <http://www.assero.co.uk/VI#22b0f0c8d6218cbc9e10ab1b91c9e1f800cb4f83> ;
.
<http://www.assero.co.uk/TP#ad23aff2-518d-4d33-9178-48fbe55745c4>
	rdf:type pr:Timepoint ;
	isoC:label "TP5"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#bf735ac0-974f-4411-a536-13c101cb688d> ;
	pr:inVisit <http://www.assero.co.uk/VI#409a2e79a0b954569269055689ebe4053add5292> ;
.
<http://www.assero.co.uk/IC#1c9dea95-7da9-4d32-a8df-da1126424afe>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "0"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#88eabc08-fa7f-4058-a6ad-71bf8a9ccf39>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "4838400"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#6800ec9c-467d-4f09-a580-48ab7899ff45>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "7257600"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#8be0c03d-1fb0-48e6-831e-40dd78b8beaa>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "9676800"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#bf735ac0-974f-4411-a536-13c101cb688d>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "14515200"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#c95f179a-4145-4baa-8f9b-38acb92c231a>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ1"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the effect of Xanomeline Transdermal Therapeutic System (TTS) on the ADAS-Cog and CIBIC+ scores at Week 24 in participants with Mild to Moderate Alzheimerâ€™s Disease"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#a9a96ec019494d5b8b041c1d2468061ae66e35d5> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_1/V1#OB> ;
.
<http://www.assero.co.uk/IC#8e2a7283-b37b-4fc7-8e40-010237c76845>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ2"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#a9a96ec019494d5b8b041c1d2468061ae66e35d5> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_3/V1#OB> ;
.
<http://www.assero.co.uk/IC#099a3fb9-8c0c-4c1d-a02e-6503fa74503c>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ3"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To document the safety profile of the xanomeline TTS."^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_4/V1#OB> ;
.
<http://www.assero.co.uk/IC#cda5dd26-c854-40e3-a7d8-df8b4ac3085b>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ4"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the effect of xanomeline TTS on the measure of behavioral/neuropsychiatric symptoms in participants with  Alzheimerâ€™s Disease"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_5/V1#OB> ;
.
<http://www.assero.co.uk/IC#9b7118b9-a5c8-4b1b-9ed0-0e6a86e35e7e>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ5"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas"^^xsd:string ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
	pr:derivedFrom <http://www.transceleratebiopharmainc.com/OBJ_6/V1#OB> ;
.
<http://www.assero.co.uk/IC#d713c782-dc7f-4864-8f48-a90903ce87ad>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP1"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8, 16 and 24 in the Alzheimerâ€™s Disease Assessment Scale â€“ Cognitive Assessment (ADAS-Cog) 14 total score"^^xsd:string ;
.
<http://www.assero.co.uk/IC#ce3e803c-a39c-40b6-82d2-ba2c2ba69a2e>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP2"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8, 16 and 24 in the Clinicianâ€™s Interview-Based Impression of Change plus caregiver input (CIBIC+)"^^xsd:string ;
.
<http://www.assero.co.uk/IC#d9923047-16d8-420b-9170-e22790d93f3e>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP3"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the Neuropsychiatric Inventory (NPI) total score"^^xsd:string ;
.
<http://www.assero.co.uk/IC#04ba9c4a-090e-486f-a90d-38f7cb55b124>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP4"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The proportion of participants with adverse events, serious adverse events (SAEs), and adverse events leading to study intervention discontinuation over the 24-week study intervention period"^^xsd:string ;
.
<http://www.assero.co.uk/IC#afb93fa2-9755-4b8c-9e5b-f9025459ca14>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP5"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 12 in continuous laboratory tests: Hepatic Function Panel"^^xsd:string ;
.
<http://www.assero.co.uk/IC#7959cd07-fff1-439c-bdc2-1cd3d1c7ccef>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP6"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The proportion of participants with abnormal (high or low) laboratory measures (urinalysis) during the postrandomization phase"^^xsd:string ;
.
<http://www.assero.co.uk/IC#e73bdf7e-d62a-4cc6-af11-be4c5b017037>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP7"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in ECG parameter: QTcF"^^xsd:string ;
.
<http://www.assero.co.uk/IC#cf0c6b4d-e19e-4ac5-bfdc-6c2a2df4377a>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP8"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the Neuropsychiatric Inventory (NPI) total score"^^xsd:string ;
.
<http://www.assero.co.uk/IC#b0747415-6398-40ef-9ed2-6f2f66fdf685>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP9"^^xsd:string ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the DAD total score"^^xsd:string ;
.